2019 CTRC-AACR San Antonio Breast Cancer Symposium*

Download All
December 10-14, 2019; San Antonio, Texas
Review slidesets and analyses of key data from the 2019 Breast Cancer meeting.

Breast Cancer

Capsule Summary Slidesets

In patients with HER2+ MBC and previous treatment with trastuzumab, pertuzumab, and T-DM1, tucatinib in combination with trastuzumab and capecitabine substantially extended survival outcomes compared with trastuzumab and capecitabine alone, including in patients with brain metastases.

Released: December 16, 2019

In patients with HER2+ metatstatic breast cancer after prior anti-HER2 therapy, margetuximab + chemotherapy continues to provide PFS benefit vs trastuzumab + chemotherapy with similar OS benefit in the second interim survival analysis of SOPHIA.

Released: December 20, 2019

In patients with HER2+ unresectable or metastatic breast cancer who were previously treated with T-DM1, trastuzumab deruxtecan achieved strong, durable benefit.

Released: December 18, 2019

Continued significant improvement in invasive disease–free survival but not OS evident with addition of pertuzumab to adjuvant chemotherapy plus trastuzumab in patients with HER2+ EBC with 6-year follow-up.

Released: December 16, 2019

Phase II ATEMPT trial shows very few recurrences with adjuvant T-DM1 but similar rates of AEs as TH at 3-year follow-up in patients with stage I HER2-positive breast cancer.

Released: December 19, 2019

No significant differences in PFS benefit between palbociclib plus endocrine therapy and single-agent capecitabine, including in women with visceral disease, ESR1 wildtype tumors, and luminal breast cancer, but combination better tolerated.

Released: December 20, 2019

Neoadjuvant pembrolizumab plus chemotherapy associated with pCR benefit vs chemotherapy alone in patients with early-stage TNBC across multiple subgroups.

Released: December 19, 2019

No significant increase in pCR rate with addition of atezolizumab to carboplatin/nab-paclitaxel in women with early, high-risk and locally advanced TNBC.

Released: December 19, 2019

Patients with advanced breast cancer and rare mutations identified by ctDNA testing responded to matched targeted therapies.

Released: December 20, 2019

In patients with HR+ early breast cancer, use of extended adjuvant letrozole after previous adjuvant AI therapy significantly improved disease-free survival with longer-term follow-up.

Released: December 19, 2019

Oral paclitaxel significantly improved confirmed ORR with less neuropathy and more gastrointestinal toxicity vs IV paclitaxel in MBC.

Released: December 20, 2019

In the randomized phase II INFORM trial, rates of pCR and RCB 0/1 were similar with cisplatin vs AC in patients with early-stage breast cancer and germline BRCA mutations.

Released: December 17, 2019

In heavily pretreated patients with HER2-expressing breast cancer, trastuzumab deruxtecan did not result in clinically meaningful prolongation of QTc interval and was associated with a manageable safety profile and antitumor activity.

Released: December 20, 2019

Neratinib with or without fulvestrant was well tolerated and active in patients with advanced breast cancer and HER2 mutations identified by ctDNA testing.

Released: December 17, 2019

In patients with HER2+ breast cancer and CNS metastases, use of neratinib-based therapy showed CNS activity in this combined analysis of 3 clinical trials.

Released: December 20, 2019

Structured loperamide prophylaxis reduced the incidence, severity, and duration of treatment-associated diarrhea in patients with HER2+ early breast cancer receiving extended adjuvant neratinib therapy after trastuzumab-based adjuvant therapy.

Released: December 16, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue